Does early treatment of Rheumatoid Arthritis lead to a better long-term prognosis?;¿El control precoz de la artritis reumatoide augura un mejor pronóstico a largo plazo?

Reumatologia Clinica

Volumn 6, Issue 2, 2010, Pages 106-110

  Villaverde García, Virginia ^a   Balsa Criado, Alejandro ^b  

^a HOSPITAL DE MÓSTOLES   (Spain)

^b HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

AntiTNF; Early response; PEGilation; Rheumatoid arthritis; Treatment

Indexed keywords

TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ARTHROPATHY; EARLY INTERVENTION; INFLAMMATION; PROGNOSIS; REMISSION; REVIEW; RHEUMATOID ARTHRITIS;

EID: 75849149002     PISSN: 1699258X     EISSN: 18851398     Source Type: Journal    
DOI: 10.1016/j.reuma.2009.10.007     Document Type: Review

References (66)

1. Carmona L., Villaverde V., Hernández-García C., Ballina J., Gabriel R., Laffon A., et al. The prevalence of rheumatoid arthritis in the general population of Spain. Rheumatology (Oxford) 41 (2002) 88-95
2. Gabriel S.E., Crowson C.S., and O'Fallon W.M. The epidemiology of rheumatoid arthritis in Rochester, Minnesota, 1955-1985. Arthritis Rheum 42 (1999) 415-420
3. Plant M.J., Jones P.W., Saklatvala J., Ollier W.E., and Dawes P.T. Patterns of radiological progression in early rheumatoid arthritis: results of an 8 year prospective study. J Rheumatol 25 (1998) 417-426
4. Sherrer Y.S., Bloch D.A., Mitchell D.M., Young D.Y., and Fries J.F. The development of disability in rheumatoid arthritis. Arthritis Rheum 29 (1986) 494-500
5. Sokka T., and Makinen H. Drug management of early rheumatoid arthritis-2008. Best Pract Res Clin Rheumatol 23 (2009) 93-102
6. Combe B., Landewe R., Lukas C., Bolosiu H.D., Breedveld F., Dougados M., et al. EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 66 (2007) 34-45
7. Combe B. Early rheumatoid arthritis: strategies for prevention and management. Best Pract Res Clin Rheumatol 21 (2007) 27-42
8. Hayer S., Redlich K., Korb A., Hermann S., Smolen J., and Schett G. Tenosynovitis and osteoclast formation as the initial preclinical changes in a murine model of inflammatory arthritis. Arthritis Rheum 56 (2007) 79-88
9. Ostergaard M., Ejbjerg B., and Szkudlarek M. Imaging in early rheumatoid arthritis: roles of magnetic resonance imaging, ultrasonography, conventional radiography and computed tomography. Best Pract Res Clin Rheumatol 19 (2005) 91-116
10. Buckland-Wright J.C., Clarke G.S., Chikanza I.C., and Grahame R. Quantitative microfocal radiography detects changes in erosion area in patients with early rheumatoid arthritis treated with myocrisine. J Rheumatol 20 (1993) 243-247
11. van der Heijde D.M., Jacobs J.W., Bijlsma J.W., Heurkens A.H.M., van B.-F.C., van-der V.M.B., et al. The effectineness of early treatment with "second-line" antirheumatic drugs. A randomized, controlled trial. Ann Intern Med 124 (1996) 699-707
12. Tsakonas E., Fitzgerald A.A., Fitzcharles M.A., Cividino A., Thorne J.C., S'Seffar A., et al. Consequences of delayed therapy with second-line agents in rheumatoid arthritis: a 3 year followup on the hydroxychloroquine in early rheumatoid arthritis (HERA) study. J Rheumatol 27 (2000) 623-629
13. Nell V.P., Machold K.P., Eberl G., Stamm T.A., Uffmann M., and Smolen J.S. Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. Rheumatology (Oxford) 43 (2004) 906-914
14. Mottonen T., Hannonen P., Korpela M., Nissila M., Kautiainen H., Ilonen J., et al. Delay to institution of therapy and induction of remission using single-drug or combination-disease-modifying antirheumatic drug therapy in early rheumatoid arthritis. Arthritis Rheum 46 (2002) 894-898
15. Cush J.J. Early arthritis clinics: if you build it will they come?. J Rheumatol 32 (2005) 203-207
16. Villaverde V., and Balsa A. Factores pronósticos de la artritis reumatoide. Rev Esp Reumatol 29 (2002) 10-15
17. Andreu J.L., Silva L., Sanz J., and Muñoz P. Optimización del tratamiento clásico de la artritis reumatoide. Reumatol Clin 2 Suppl 2 (2006) 51-58
18. Green D., Marzo-Ortega H., McGonagle D., Wakefield R.J., Proudman S.M., Conaghan P.G., et al. Persistence of mild, early inflammatory arthritis: the importance of disease duration, rheumatoid factor, and the shared epitope. Arthritis Rheum 42 (1999) 2184-2188
19. Lard L.D., Visser H., Speyer I., van-der H.-B.I.E., Zwinderman A.H., Breedveld F.C., et al. Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies. Am J Med 111 (2001) 446-451
20. Anderson J.J., Wells G., Verhoeven A.C., and Felson D.T. Factors predicting response to treatment in rheumatoid arthritis: the importance of disease duration. Arthritis Rheum 43 (2000) 22-29
21. Finckh A., Liang M.H., van Herckenrode C.M., and de Pablo P. Long-term impact of early treatment on radiographic progression in rheumatoid arthritis: A meta-analysis. Arthritis Rheum 55 (2006) 864-872
22. Emery P., Breedveld F.C., Dougados M., Kalden J.R., Schiff M.H., and Smolen J.S. Early referral recommendation for newly diagnosed rheumatoid arthritis: evidence based development of a clinical guide. Ann Rheum Dis 61 (2002) 290-297
23. Martínez A., Batlle G.E., and Pascual E. Curso y evolución de la artritis reumatoide. Factores pronósticos. Semin Fund Esp Reumatol 1 (2000) 65-72
24. Villaverde V., Balsa A., and Martín-Mola E. Estrategias para un diagnóstico y tratamiento precoz de la artritis reumatoide. Implantación de consultas de artritis de reciente comienzo. Semin Fund Esp Reumatol 1 (2000) 3-9
25. Machold K.P., Eberl G., Leeb B.F., Nell V., Windisch B., and Smolen J.S. Early arthritis therapy: rationale and current approach. J Rheumatol Suppl 53 (1998) 13-19
26. Smolen J.S., and Aletaha D. Developments in the clinical understanding of rheumatoid arthritis. Arthritis Res Ther 11 (2009) 204
27. Scott D.L., Smith C., and Kingsley G. Joint damage and disability in rheumatoid arthritis: an updated systematic review. Clin Exp Rheumatol 21 Suppl 31 (2003) S20-S27
28. Smolen J.S., van der Heijde D.M., Aletaha D., Xu S., Han J., Baker D., et al. Progression of radiographic joint damage in rheumatoid arthritis: Independence of erosions and joint space narrowing. Ann Rheum Dis 68 (2009) 1535-1540
29. Wakefield R.J., Green M.J., Marzo-Ortega H., Conaghan P.G., Gibbon W.W., McGonagle D., et al. Should oligoarthritis be reclassified? Ultrasound reveals a high prevalence of subclinical disease. Ann Rheum Dis 63 (2004) 382-385
30. Goupille P., Roulot B., Akoka S., Avimadje A.M., Garaud P., Naccache L., et al. Magnetic resonance imaging: a valuable method for the detection of synovial inflammation in rheumatoid arthritis. J Rheumatol 28 (2001) 35-40
31. Wakefield R.J., Freeston J.E., Hensor E.M., Bryer D., Quinn M.A., and Emery P. Delay in imaging versus clinical response: a rationale for prolonged treatment with anti-tumor necrosis factor medication in early rheumatoid arthritis. Arthritis Rheum 57 (2007) 1564-1567
32. Pincus T. Rheumatology function tests: quantitative physical measures to monitor morbidity and predict mortality in patients with rheumatic diseases. Clin Exp Rheumatol 23 5 Suppl 39 (2005) S85-S89
33. Combe B., Cantagrel A., Goupille P., Bozonnat M.C., Sibilia J., Eliaou J.F., et al. Predictive factors of 5-year health assessment questionnaire disability in early rheumatoid arthritis. J Rheumatol 30 (2003) 2344-2349
34. Aletaha D., Smolen J., and Ward M.M. Measuring function in rheumatoid arthritis: Identifying reversible and irreversible components. Arthritis Rheum 54 (2006) 2784-2792
35. Aletaha D., Strand V., Smolen J.S., and Ward M.M. Treatment-related improvement in physical function varies with duration of rheumatoid arthritis: a pooled analysis of clinical trial results. Ann Rheum Dis 67 (2008) 238-243
36. Pollard L., Choy E.H., and Scott D.L. The consequences of rheumatoid arthritis: quality of life measures in the individual patient. Clin Exp Rheumatol 23 5 Suppl 39 (2005) S43-S52
37. del R.I., Williams K., Stern M.P., Freeman G.L., and Escalante A. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 44 (2001) 2737-2745
38. Nicola P.J., Maradit-Kremers H., Roger V.L., Jacobsen S.J., Crowson C.S., Ballman K.V., et al. The risk of congestive heart failure in rheumatoid arthritis: a population-based study over 46 years. Arthritis Rheum 52 (2005) 412-420
39. Goodson N.J., Wiles N.J., Lunt M., Barrett E.M., Silman A.J., and Symmons D.P. Mortality in early inflammatory polyarthritis: cardiovascular mortality is increased in seropositive patients. Arthritis Rheum 46 (2002) 2010-2019
40. García Díaz J.D., López de G.A., Díez-Pérez de la Vacas M.I., Cuende Q.E., and Sánchez A.A. Determinants of carotid subclinical atherosclerosis in patients with rheumatoid arthritis. A case-control study. Med Clin (Barc) 130 (2008) 210-212
41. González-Gay M.A., González-Juanatey C., and Martín J. Inflammation and endothelial dysfunction in rheumatoid arthritis. Clin Exp Rheumatol 24 (2006) 115-117
42. Del P.F., Lagana B., Lai S., Nofroni I., Tinti F., Vitale M., et al. Response to anti-tumour necrosis factor alpha blockade is associated with reduction of carotid intima-media thickness in patients with active rheumatoid arthritis. Rheumatology (Oxford) 46 (2007) 1111-1115
43. Baecklund E., Iliadou A., Askling J., Ekbom A., Backlin C., Granath F., et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum 54 (2006) 692-701
44. Pincus T., Callahan L.F., Sale W.G., Brooks A.L., Payne L.E., and Vaughn W.K. Severe functional declines, work disability, and increased mortality in seventy-five rheumatoid arthritis patients studied over nine years. Arthritis Rheum 27 (1984) 864-872
45. Wells G., Boers M., and Tugwell P. Low disease activity state in rheumatoid arthritis: concepts and derivation of minimal disease activity. Clinical Experimental Rheumatology 24 6 Suppl 43 (2006) S9
46. Kievit W., Fransen J., Oerlemans A.J., Kuper H.H., van der Laar M.A., de Rooij D.J., et al. The efficacy of anti-TNF in rheumatoid arthritis, a comparison between randomised controlled trials and clinical practice. Ann Rheum Dis 66 (2007) 1473-1478
47. Breedveld F.C., Weisman M.H., Kavanaugh A.F., Cohen S.B., Pavelka K., van V.R., et al. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 54 (2006) 26-37
48. Emery P., Breedveld F.C., Hall S., Durez P., Chang D.J., Robertson D., et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet 372 (2008) 375-382
49. van der Kooij S.M., de Vries-Bouwstra J.K., Goekoop-Ruiterman Y.P., van Z.D., Kerstens P.J., Gerards A.H., et al. Limited efficacy of conventional DMARDs after initial methotrexate failure in patients with recent onset rheumatoid arthritis treated according to the disease activity score. Ann Rheum Dis 66 (2007) 1356-1362
50. Aletaha D., Funovits J., Keystone E.C., and Smolen J.S. Disease activity early in the course of treatment predicts response to therapy after one year in rheumatoid arthritis patients. Arthritis Rheum 56 (2007) 3226-3235
51. Aletaha D., Funovits J., Breedveld F.C., Sharp J., Segurado O., and Smolen J.S. Rheumatoid arthritis joint progression in sustained remission is determined by disease activity levels preceding the period of radiographic assessment. Arthritis Rheum 60 (2009) 1242-1249
52. Smolen J.S., Han C., van der Heijde D.M., Emery P., Bathon J.M., Keystone E., et al. Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and TNF-blockade. Ann Rheum Dis 68 (2009) 823-827
53. Bejarano V., Quinn M., Conaghan P.G., Reece R., Keenan A.M., Walker D., et al. Effect of the early use of the anti-tumor necrosis factor adalimumab on the prevention of job loss in patients with early rheumatoid arthritis. Arthritis Rheum 59 (2008) 1467-1474
54. Puolakka K., Kautiainen H., Mottonen T., Hannonen P., Korpela M., Hakala M., et al. Early suppression of disease activity is essential for maintenance of work capacity in patients with recent-onset rheumatoid arthritis: five-year experience from the FIN-RACo trial. Arthritis Rheum 52 (2005) 36-41
55. Rantalaiho V., Korpela M., Hannonen P., Kautiainen H., Jarvenpaa S., Leirisalo-Repo M., et al. The good initial response to therapy with a combination of traditional disease-modifying antirheumatic drugs is sustained over time: the eleven-year results of the Finnish rheumatoid arthritis combination therapy trial. Arthritis Rheum 60 (2009) 1222-1231
56. Luqmani R., Hennell S., Estrach C., Birrell F., Bosworth A., Davenport G., et al. British Society for Rheumatology and British Health Professionals in Rheumatology Guideline for the Management of Rheumatoid Arthritis (The first 2 years). Rheumatology (Oxford) 48 (2009) 436-439
57. Saag K.G., Teng G.G., Patkar N.M., Anuntiyo J., Finney C., Curtis J.R., et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 59 (2008) 762-784
58. Cohen S., Cannon G.W., Schiff M., Weaver A., Fox R., Olsen N., et al. Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Utilization of Leflunomide in the Treatment of Rheumatoid Arthritis Trial Investigator Group. Arthritis Rheum 44 (2001) 1984-1992
59. Siddiqui M.A. The efficacy and tolerability of newer biologics in rheumatoid arthritis: best current evidence. Curr Opin Rheumatol 19 (2007) 308-313
60. St Clair E.W., van der Heijde D.M., Smolen J.S., Maini R.N., Bathon J.M., Emery P., et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 50 (2004) 3432-3443
61. Bathon J.A., Martin R.W., Fleischmann R.M., Tesser J.R., Schiff M.H., Keystone E.C., et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 343 (2000) 1586-1593
62. Keystone E., Heijde D., Mason Jr. D., Landewe R., Vollenhoven R.V., Combe B., et al. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 58 (2008) 3319-3329
63. Goekoop-Ruiterman Y.P., de Vries-Bouwstra J.K., Allaart C.F., van Z.D., Kerstens P.J., Hazes J.M., et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 52 (2005) 3381-3390
64. Goekoop-Ruiterman Y.P., de Vries-Bouwstra J.K., Allaart C.F., Kerstens P.J., Grillet B.A., de Jager M.H., et al. Patient preferences for treatment: report from a randomised comparison of treatment strategies in early rheumatoid arthritis (BeSt trial). Ann Rheum Dis 66 (2007) 1227-1232
65. van der Heijde DM, Weinblatt ME, Landewe R, Goel N, Wells AF, Fleischmann R. Inhibition of progression of structural damage by week 16 with certolizumab pegol: results from the RAPID trials, Arthritis and Rheumatism 58 (Abstract Suplement), 51, 2008
66. van Tuyl L.H., Plass A.M., Lems W.F., Voskuyl A.E., Dijkmans B.A., and Boers M. Why are Dutch rheumatologists reluctant to use the COBRA treatment strategy in early rheumatoid arthritis?. Ann Rheum Dis 66 (2007) 974-976